Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies.

Q1 Medicine

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI:10.56875/2589-0646.1030

Yang Yang, Xia Bi, Mia Gergis, Dongni Yi, Jingmei Hsu, Usama Gergis

{"title":"Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies.","authors":"Yang Yang, Xia Bi, Mia Gergis, Dongni Yi, Jingmei Hsu, Usama Gergis","doi":"10.56875/2589-0646.1030","DOIUrl":null,"url":null,"abstract":"<p><p>Autologous chimeric antigen receptor (CAR) T cell therapy has been extensively studied over the past decades. Currently, autologous CAR T products are FDA-approved to treat B cell acute lymphoblastic leukemia (B-ALL), large B cell, mantle cell, and follicular lymphomas, and multiple myeloma. However, this therapy has drawbacks including higher cost, production lead time, logistical complexity, and higher risk of manufacturing failure. Alternatively, allogeneic CAR T cell therapy, currently under clinical trial, has inherent disadvantages, including cell rejection, graft versus host disease, and undetermined safety and efficacy profiles. Different strategies, including modifying HLA and T cell receptor expression using different effector cells, are under investigation to circumvent these issues. Early allogeneic CAR T therapy results for B-ALL and B-NHL have been promising. Large sample clinical trials are ongoing. Here, we discuss the pros and cons of allo-CAR T for hematologic malignancies and review the latest data on this scalable approach.</p>","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 3","pages":"112-116"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/ Oncology and Stem Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56875/2589-0646.1030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Autologous chimeric antigen receptor (CAR) T cell therapy has been extensively studied over the past decades. Currently, autologous CAR T products are FDA-approved to treat B cell acute lymphoblastic leukemia (B-ALL), large B cell, mantle cell, and follicular lymphomas, and multiple myeloma. However, this therapy has drawbacks including higher cost, production lead time, logistical complexity, and higher risk of manufacturing failure. Alternatively, allogeneic CAR T cell therapy, currently under clinical trial, has inherent disadvantages, including cell rejection, graft versus host disease, and undetermined safety and efficacy profiles. Different strategies, including modifying HLA and T cell receptor expression using different effector cells, are under investigation to circumvent these issues. Early allogeneic CAR T therapy results for B-ALL and B-NHL have been promising. Large sample clinical trials are ongoing. Here, we discuss the pros and cons of allo-CAR T for hematologic malignancies and review the latest data on this scalable approach.

查看原文本刊更多论文

同种异体嵌合抗原受体T细胞用于血液恶性肿瘤。

自体嵌合抗原受体(CAR) T细胞治疗在过去的几十年里得到了广泛的研究。目前，自体CAR - T产品已被fda批准用于治疗B细胞急性淋巴细胞白血病(B- all)、大B细胞、套细胞、滤泡性淋巴瘤和多发性骨髓瘤。然而，这种疗法存在成本高、生产前置时间长、物流复杂、生产失败风险高等缺点。另外，目前正在进行临床试验的同种异体CAR - T细胞疗法具有固有的缺点，包括细胞排斥反应、移植物抗宿主病以及不确定的安全性和有效性。不同的策略，包括使用不同的效应细胞修改HLA和T细胞受体的表达，正在研究中，以避免这些问题。早期同种异体CAR - T治疗B-ALL和B-NHL的结果很有希望。大样本临床试验正在进行中。在这里，我们讨论了同种异体car - T治疗血液恶性肿瘤的利弊，并回顾了这种可扩展方法的最新数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology/ Oncology and Stem Cell Therapy Medicine-Hematology

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

27 weeks

期刊介绍： Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.